Michael P. Cruse
2022
In 2022, Michael P. Cruse earned a total compensation of $781.5K as Chief Operating Officer at Reneo Pharmaceuticals, a 48% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $144,000 |
|---|---|
| Option Awards | $246,000 |
| Salary | $391,474 |
| Total | $781,474 |
Cruse received $391.5K in salary, accounting for 50% of the total pay in 2022.
Cruse also received $144K in non-equity incentive plan and $246K in option awards.
Rankings
In 2022, Michael P. Cruse's compensation ranked 3,550th out of 5,756 executives tracked by ExecPay. In other words, Cruse earned more than 38.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,550 out of 5,756 | 38th |
Division Manufacturing | 2,014 out of 3,133 | 36th |
Major group Chemicals And Allied Products | 962 out of 1,419 | 32nd |
Industry group Drugs | 900 out of 1,320 | 32nd |
Industry Pharmaceutical Preparations | 655 out of 966 | 32nd |
Source: SEC filing on April 26, 2023.
Cruse's colleagues
We found two more compensation records of executives who worked with Michael P. Cruse at Reneo Pharmaceuticals in 2022.